Cargando…
Digital therapeutics and clinical pharmacology
Digital therapeutics (DTx) is a new subsection of digital health that is primarily driven by software and will be of great interest to clinical pharmacologists. In this article, an overview of DTx, including definition, position in the landscape of therapeutics, product categories, benefits, and cha...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society for Clinical Pharmacology and Therapeutics
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989269/ https://www.ncbi.nlm.nih.gov/pubmed/32055575 http://dx.doi.org/10.12793/tcp.2019.27.1.6 |
_version_ | 1783492371830276096 |
---|---|
author | Chung, Jae-Yong |
author_facet | Chung, Jae-Yong |
author_sort | Chung, Jae-Yong |
collection | PubMed |
description | Digital therapeutics (DTx) is a new subsection of digital health that is primarily driven by software and will be of great interest to clinical pharmacologists. In this article, an overview of DTx, including definition, position in the landscape of therapeutics, product categories, benefits, and challenges, is provided. Discussions from the point of view of clinical pharmacology are presented, as DTx should have exposure-response relationships. The principles of clinical pharmacology can be applied to DTx as they are comparable to pharmacotherapy. Clinical pharmacology has great potential in the development, application, and regulation of DTx. |
format | Online Article Text |
id | pubmed-6989269 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Korean Society for Clinical Pharmacology and Therapeutics |
record_format | MEDLINE/PubMed |
spelling | pubmed-69892692020-02-13 Digital therapeutics and clinical pharmacology Chung, Jae-Yong Transl Clin Pharmacol Review Digital therapeutics (DTx) is a new subsection of digital health that is primarily driven by software and will be of great interest to clinical pharmacologists. In this article, an overview of DTx, including definition, position in the landscape of therapeutics, product categories, benefits, and challenges, is provided. Discussions from the point of view of clinical pharmacology are presented, as DTx should have exposure-response relationships. The principles of clinical pharmacology can be applied to DTx as they are comparable to pharmacotherapy. Clinical pharmacology has great potential in the development, application, and regulation of DTx. Korean Society for Clinical Pharmacology and Therapeutics 2019-03 2019-03-27 /pmc/articles/PMC6989269/ /pubmed/32055575 http://dx.doi.org/10.12793/tcp.2019.27.1.6 Text en Copyright © 2019 Jae-Yong Chung http://creativecommons.org/licenses/by-nc/3.0/ It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/). |
spellingShingle | Review Chung, Jae-Yong Digital therapeutics and clinical pharmacology |
title | Digital therapeutics and clinical pharmacology |
title_full | Digital therapeutics and clinical pharmacology |
title_fullStr | Digital therapeutics and clinical pharmacology |
title_full_unstemmed | Digital therapeutics and clinical pharmacology |
title_short | Digital therapeutics and clinical pharmacology |
title_sort | digital therapeutics and clinical pharmacology |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6989269/ https://www.ncbi.nlm.nih.gov/pubmed/32055575 http://dx.doi.org/10.12793/tcp.2019.27.1.6 |
work_keys_str_mv | AT chungjaeyong digitaltherapeuticsandclinicalpharmacology |